TY - JOUR
T1 - Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction
AU - Hoemann, Benjamin
AU - Takayama, Hiroo
AU - Jennings, Douglas L.
AU - Han, Jiho
AU - Ando, Masahiko
AU - Restaino, Susan
AU - Colombo, Paolo
AU - Farr, Maryjane
AU - Naka, Yoshifumi
AU - Takeda, Koji
N1 - Funding Information:
This project was supported by a grant from the National Institute of Health T35 medical student summer research program (5T35HL007616-37).
Funding Information:
This project was supported by a grant from the National Institute of Health T35 medical student summer research program (5T35HL007616‐37).
Publisher Copyright:
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Background: Recent studies have shown an increased incidence of primary graft dysfunction (PGD) in patients treated with amiodarone prior to orthotopic heart transplant (OHT). We hypothesized that discontinuation of amiodarone before OHT may lower the incidence of severe PGD. Methods: This was a single-center retrospective study of 381 adult OHT recipients between January 2010 and June 2017. Within 6 months prior to OHT, 197 did not receive amiodarone (Group 1), 142 continued amiodarone to OHT (Group 2), and 42 had amiodarone treatment discontinued before OHT (Group 3). Results: 53 (13.9%) participants developed severe PGD, 13 (6.6%) of which were in Group 1, 36 (25.4%) were in Group 2, and 4 (9.5%) were in Group 3 (P <.001). Multivariable analysis revealed continued amiodarone treatment to OHT (Group 2; OR, 3.70; 95% CI, 1.26-10.88; P =.018) to be an independent risk factor for the development of severe PGD when Group 1 served as the reference group. Moreover, patients in Group 3 had no difference in the risk of severe PGD (OR = 0.416, 95% CI = 0.08-2.15; P =.296). Conclusion: We found that discontinuing amiodarone treatment prior to OHT resulted a lower incidence of severe PGD.
AB - Background: Recent studies have shown an increased incidence of primary graft dysfunction (PGD) in patients treated with amiodarone prior to orthotopic heart transplant (OHT). We hypothesized that discontinuation of amiodarone before OHT may lower the incidence of severe PGD. Methods: This was a single-center retrospective study of 381 adult OHT recipients between January 2010 and June 2017. Within 6 months prior to OHT, 197 did not receive amiodarone (Group 1), 142 continued amiodarone to OHT (Group 2), and 42 had amiodarone treatment discontinued before OHT (Group 3). Results: 53 (13.9%) participants developed severe PGD, 13 (6.6%) of which were in Group 1, 36 (25.4%) were in Group 2, and 4 (9.5%) were in Group 3 (P <.001). Multivariable analysis revealed continued amiodarone treatment to OHT (Group 2; OR, 3.70; 95% CI, 1.26-10.88; P =.018) to be an independent risk factor for the development of severe PGD when Group 1 served as the reference group. Moreover, patients in Group 3 had no difference in the risk of severe PGD (OR = 0.416, 95% CI = 0.08-2.15; P =.296). Conclusion: We found that discontinuing amiodarone treatment prior to OHT resulted a lower incidence of severe PGD.
KW - amiodarone
KW - heart failure
KW - orthotopic heart transplantation
KW - primary graft dysfunction
UR - http://www.scopus.com/inward/record.url?scp=85079354443&partnerID=8YFLogxK
U2 - 10.1111/ctr.13779
DO - 10.1111/ctr.13779
M3 - Article
C2 - 31903624
AN - SCOPUS:85079354443
SN - 0902-0063
VL - 34
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 2
M1 - e13779
ER -